Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vytorin, Zetia Coverage In 2009 Among All Payers Still Solid But Slipping

Executive Summary

Merck/Schering-Plough's cholesterol drugs Vytorin and Zetia will be reimbursed without restriction as preferred brands for about 67 percent of individuals enrolled in commercial and Medicare Part D plans in 2009, according to Merck
Advertisement

Related Content

Merck's Ezetimibe Faces Reimbursement Threat In Europe
Vytorin Won’t Be ENHANCEd By Part D In 2009: Formulary Review
Vytorin Won’t Be ENHANCEd By Part D In 2009: Formulary Review
Advertisement
UsernamePublicRestriction

Register

PS050275

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel